00:00
319
Dr. Brian Druker, Director of the OHSU Knight Cancer Institute, shares how what he and his colleagues have learned in the study of Chronic Myelogenous Leukemia (CML) has forwarded a personalized medicine approach - something he believes is simply an extension of compassionate care.
Loading more stuff…